Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-7 (Accession number: KCTC 13247BP) isolated from nature, which has the ability to kill Vibrio parahaemolyticus and has the genome represented by SEQ ID NO: 1, and a method for preventing or treating a disease caused by Vibrio parahaemolyticus using a composition containing the Myoviridae bacteriophage Vib-PAP-7 as an active ingredient.

Abstract: A sample protection method is provided which may be used for protecting a biological sample on a microscope slide, such as during heat-induced target retrieval and/or after heat-induced target retrieval such that: 1) the sample remains adherent to the microscope slide; and 2) the microscopic morphology of the biological sample remains intact. In some embodiments, the sample protection method may include the steps of: creating a sectioned sample that is in contact with a microscope slide; applying a protecting reagent onto a sectioned sample that is in contact with a microscope slide and drying the protecting reagent in which the protecting reagent may be both applied and dried onto the sectioned sample before and/or after performing target retrieval on the sectioned sample. The protecting reagent may include a water-soluble polymer and/or a water-soluble wax, such as polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, alginic acid, and carrageenan.

Abstract: The present invention relates to methods and compositions for diagnosing and treating degenerative mitral valve disease in a canine. In one embodiment, a method of diagnosing early stage degenerative mitral valve disease in a canine can comprise measuring a normalized relative abundance of a biomarker selected from the group consisting of Erysipelatoclostridium, Ruminococcaceae UCG014, Butyricicoccus, Faecalibacterium, and combinations thereof, and determining that the canine has early stage degenerative mitral valve disease if the Erysipelatoclostridium is from 0 to 0.5 normalized relative abundance, the Ruminococcaceae UCG014 is from 0 to 0.1 normalized relative abundance, the Butyricicoccus is from 0 to 0.1 normalized relative abundance, or the Faecalibacterium is from 0 to 0.1 normalized relative abundance.

Abstract: A blood component separation device for separating a plurality of blood components from blood sampled from a blood donor, and collecting platelets, includes: an operation unit that calculates a predicted platelet recovery rate from a hematocrit value of the blood and a platelet concentration of the blood, and calculates a recommended processing amount of the blood recommended for collecting a target number of units of platelets on the basis of the calculated predicted platelet recovery rate, wherein the operating unit sets the predicted platelet recovery rate calculated from any the hematocrit value and any the platelet concentration to be smaller by a predetermined value a when the blood donor is female than that when the blood donor is male.

Abstract: Pharmaceutical compositions containing microbial entities are described herein. The pharmaceutical compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the pharmaceutical compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

Abstract: The present invention relates to a composition comprising at least one selected from the group consisting of a novel lactic acid bacterium, Lactobacillus plantarum KBL396 (KCTC13278BP), culture of the strain, lysate of the strain and extract of the strain, and its use for food and medicine. The strain and composition according to the present invention has an excellent effect on improvement of neurological diseases, particularly improvement of mental disorders and neurodegenerative diseases, and has no risk of side effects in a human body, and thus it can be usefully utilized as a use for improvement of neurological diseases.

Abstract: Disclosed is a combination of two or more lipase enzymes, and its use for treating a lipid digestion deficiency and/or a digestive disorder. At least one lipase enzyme has a pH optimum at an acidic pH value, while at least one other lipase enzyme has a pH optimum at an alkalic pH value.

Abstract: In alternative embodiments, the invention provides enema delivery systems or enema products comprising compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal.

Abstract: Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.

Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, for inducing the purgation of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual.

Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, for inducing the purgation of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual.